Full Text View
Tabular View
No Study Results Posted
Related Studies
Baclofen for the Treatment of Cocaine Dependence - 1
This study has been completed.
Study NCT00082485   Information provided by National Institute on Drug Abuse (NIDA)
First Received: May 11, 2004   Last Updated: May 14, 2009   History of Changes

May 11, 2004
May 14, 2009
June 2004
July 2006   (final data collection date for primary outcome measure)
Effects of medication on cocaine craving
Same as current
Complete list of historical versions of study NCT00082485 on ClinicalTrials.gov Archive Site
 
 
 
Baclofen for the Treatment of Cocaine Dependence - 1
Multi-Center Trial of Baclofen for the Treatment of Cocaine Dependence

The purpose of this study is to assess the efficacy and safety of baclofen for the treatment of cocaine dependence.

Double-blind, placebo-controlled, parallel design trial of baclofen for the treatment of cocaine dependence

Phase II
Interventional
Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study
Cocaine-Related Disorders
  • Drug: Baclofen
  • Other: Placebo
 
Kahn R, Biswas K, Childress AR, Shoptaw S, Fudala PJ, Gorgon L, Montoya I, Collins J, McSherry F, Li SH, Chiang N, Alathari H, Watson D, Liberto J, Beresford T, Stock C, Wallace C, Gruber V, Elkashef A. Multi-center trial of baclofen for abstinence initiation in severe cocaine-dependent individuals. Drug Alcohol Depend. 2009 May 2; [Epub ahead of print]

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Completed
160
November 2005
July 2006   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subject must have DSM-IV diagnosis of cocaine dependence.
  • Subject must be seeking treatment for cocaine dependence.
  • Be be able to verbalize understanding of consent form, provide written consent and verbalize willingness to complete study procedures.

Exclusion Criteria:

  • Please contact site for more information.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00082485
Liza Gorgon, National Institute on Drug Abuse
NIDA-CSP-1021-1
National Institute on Drug Abuse (NIDA)
 
Principal Investigator: Liza Gorgon, M.A. VA Maryland Health Care System
National Institute on Drug Abuse (NIDA)
May 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP